Serum carcinoembryonic antigen level as a surrogate marker for the evaluation of tumor response to chemotherapy in nonsmall cell lung cancer

Annals of Thoracic and Cardiovascular Surgery

Volumn 16, Issue 4, 2010, Pages 242-247

  Ishiguro, Futoshi ^a   Fukui, Takayuki ^a   Mori, Shoichi ^a   Katayama, Tatsuya ^a   Sakakura, Noriaki ^a   Hatooka, Shunzo ^a   Mitsudomi, Tetsuya ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

RECIST; Tumor marker; WHO

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; REMISSION; RETROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; REMISSION INDUCTION; RETROSPECTIVE STUDIES;

EID: 77958178795     PISSN: 13411098     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization Offset Publication No 48. Geneva: WHO, 1979.
2. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
3. Watanabe H, Yamamoto S, Kunitoh H, Sekine I. Yamamoto N, et al. Tumor response to chemotherapy: the validity and reproducibility of guidelines in NSCLC patients. Cancer Sci 2003; 94: 1015-20.
4. Park JO, Lee SI, Song SY, Kim K, Kim WS, et al. Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 2003; 33: 533-7.
5. Mazumdar M, Smith A, Schwartz LH. A statistical simulation study finds discordance between WHO criteria and RECIST guideline. J Clin Epidemiol 2004; 57: 358-65.
6. Vincent RG, Chu TM, Fergen TB, Takita H. Carcinoembryonic antigen in 228 patients with carcinoma of the lung. Cancer 1975; 36: 2069-76.
7. Shinkai T, Saijo N, Tominaga K, Eguchi K, Shimizu E, et al. Serial plasma carcinoembryonic antigen measurement for monitoring patients with advanced lung cancer during chemotherapy. Cancer 1986; 57: 1318-23.
8. Nisman B, Amir G, Lafair G, Heching N, Lyass O, et al. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Anticancer Res 1999; 19: 3549-52.
9. Sawabata N, Ohta M, Takeda S, Hirano H, Okumura Y, et al. Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer. Ann Thorac Surg 2002; 74: 174-9.
10. Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, et al. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease. Ann Thorac Surg 2004; 78: 216-21.
11. Hsu WH, Huang CS, Hsu HS, Huang WJ, Lee HC, et al. Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer. Ann Thorac Surg 2007; 83: 419-24.
12. Salgia R, Harpole D, Herndon JE 2nd, Pisick E, Elias A, et al. Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. Anticancer Res 2001; 21: 1241-6.
13. Konishi K, Kuriyama K, Chino S, Isohashi K, Murata M, et al. CT evaluation of response to chemotherapy and/or radiotherapy in primary lung cancer: comparison of response evaluation criteria in solid tumors (RECIST) and the WHO criteria, and comparison of both methods with the histological evaluation. Nippon Igaku Hoshasen Gakkai Zasshi 2004; 64: 41-5.
14. Watanabe H. Response evaluation. Jpn J Lung Cancer Clin 2001; 4: 111-22.
15. Satoh T, Fujita T, Yananuma Y, Moriya H, Hoshino T, et al. Clinical evaluation of serum CEA level in cases of the unresectable lung cancer. Jpn J Clin Radiol 1986; 31: 1409-13.
16. Grossi F, Belvedere O, Fasola G, Ceschia T, Meduri S, et al. Tumor measurements on computed tomographic images of non-small cell lung cancer were similar among cancer professionals from different specialties. J Clin Epidemiol 2004; 57: 804-8.
17. Ishiguro F, Mori S, Katayama T, Okuda K, Sakakura N, et al. The significance of changes in serum CEA level as a surrogate marker for evaluating tumor response to chemotherapy in non-small cell lung cancer. Japanese Journal of Lung Cancer 2008; 1: 26-32.